Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01369303 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic and Pharmacodynamic Study of Tenofovir 1% Gel
A Phase 1 study, sponsored by CONRAD.
- Completed
- Registry status
- Phase 1
- Development phase
- 194
- Enrollment target
NCT01369303 is a Phase 1 study that has completed, run by CONRAD. The registered enrollment target is 194 participants.
The verdict
NCT01369303, a Phase 1 study, has completed, sponsored by CONRAD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 194 participants
- Enrollment target
Study Summary
The purpose of the study is to obtain data on the pharmacokinetics (PK) and pharmacodynamics (PD) and immune system effect of the BAT24 dosing regimen versus daily and pericoital dosing regimens with vaginal use of tenofovir 1% gel after a single sex act and after multiple sex acts.
Interventions
- DRUG Tenofovir 1% vaginal gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2012-01 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01369303
The ClinicalTrials.gov registry entry for NCT01369303 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CONRAD, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tenofovir 1% vaginal gel is the first listed.
NCT01369303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01369303 about?
NCT01369303 is a clinical study titled "Pharmacokinetic and Pharmacodynamic Study of Tenofovir 1% Gel". The purpose of the study is to obtain data on the pharmacokinetics (PK) and pharmacodynamics (PD) and immune system effect of the BAT24 dosing regimen versus daily and pericoital dosing regimens with vaginal use of tenofovir 1% gel after a single sex act and after multiple sex acts.
What is the current status of trial NCT01369303?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 194 participants. The study started on 2012-01. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01369303?
The interventions under investigation include: Tenofovir 1% vaginal gel (DRUG).
Who is sponsoring clinical trial NCT01369303?
This trial is sponsored by CONRAD, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.